Larotinib dose study for people with liver problems
Part of Cancer, Digestive system clinical trials.
This early study (Phase 1) tests how larotinib moves through the body and is handled by the liver in people with normal liver function or mild to moderate liver impairment. The goal is to understand dosing and safety in different liver conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 to 70, and meet minimum body weight (over 50 kg if male, 45 kg or more if female).
- Your BMI must be between 18 and 30 (the study may match BMI to your liver group).
- You must either have normal liver function or mild/moderate liver impairment (based on Child-Pugh A or B scores).
- Your liver condition (if you have impairment) must be stable for about 1 month before and through the study.
- You must agree to use effective birth control and avoid pregnancy starting before the first dose and for 6 months after the last dose.
- You must have no certain health problems or test results (like HIV, active hepatitis B/C, certain cancers, or serious heart/GI/kidney issues).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests larotinib, a targeted cancer medicine, for people with advanced or recurrent esophageal cancer that has high EGFR. It aims to see if it works better than standard treatment approaches after the cancer has progressed twice.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This trial studies erlotinib, a medication used to block a growth signal, to see if it can prevent liver cancer in people with advanced liver scarring (cirrhosis or advanced fibrosis) who have never had liver cancer. It’s designed for adults with certain risk scores and good health function.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
This study tests the drug lorlatinib for people with a specific type of lung cancer (ROS1-positive non-small cell lung cancer) that has spread to the brain. It aims to see how well lorlatinib controls the brain tumors and is for those who haven't had prior treatment for brain metastases or have only had chemotherapy.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.